Janssen, FDA work on Doxil supply; DSM seeks contracts beyond Big Pharma;

> Janssen, maker of chemotherapy drug Doxil, says it's "working closely" with the FDA on a plan to get the drug to doctors as soon it becomes available, which it expects to be in late August. Story

> DSM seeks a CMO partner to help it target work in addition to what it receives from Big Pharma. Report

> Vaccine maker MedImmune has opened a second manufacturing plant in Frederick, MD, to expand production capacity. Item

> Abbott Labs will enjoy "significant savings on imports of products from offshore," after its Temecula, CA, plant was admitted to a foreign trade zone. Article

> More demand-driven supply chains can help Big Pharma make the leap from traditional make-to-stock production to more efficient make-to-demand. News

> An unnamed Belgian drugmaker is using RFID and bar code technology to track more than 70,000 bags of products annually as they undergo testing. Story

> Asian distributor Zuellig Pharma has teamed with business-process specialist ADEC Solutions to create a pharma/healthcare knowledge- and business-process outsourcing service provider. ADEC/Zuellig release

> Early results from the first few years of FDA dietary-supplement manufacturing inspections show some common GMP violations. Story

> CMO SynCo Bio Partners has expanded its aseptic filling facility, equipped to fill and lyophilize biopharmaceuticals, including monoclonal antibodies, nucleic acids, proteins, polysaccharides, aluminum-containing vaccines, RNA and live biotherapeutics for clinical and market supply. Item

> AccuDial liquid OTC medications have a two-part label that allows parents to administer milliliter-precision doses based on a child's weight, rather than the more common dosing based on age. Story

Suggested Articles

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

Boehringer Ingelheim is investing $50 million in an animal health plant in Puerto Rico, adding 105 jobs.

Teva will begin producing chemo drug vincristine in the U.S. but has resisted the idea that its withdrawal from the market led to a shortage.